» Articles » PMID: 22162545

Clostridium Difficile Carriage in Elderly Subjects and Associated Changes in the Intestinal Microbiota

Overview
Specialty Microbiology
Date 2011 Dec 14
PMID 22162545
Citations 100
Authors
Affiliations
Soon will be listed here.
Abstract

Clostridium difficile is an important nosocomial pathogen associated particularly with diarrheal disease in elderly individuals in hospitals and long-term care facilities. We examined the carriage rate of Clostridium difficile by culture as a function of fecal microbiota composition in elderly subjects recruited from the community, including outpatient, short-term respite, and long-term hospital stay subjects. The carriage rate ranged from 1.6% (n = 123) for subjects in the community, to 9.5% (n = 43) in outpatient settings, and increasing to 21% (n = 151) for patients in short- or long-term care in hospital. The dominant 072 ribotype was carried by 43% (12/28) of subjects, while the hypervirulent strain R027 (B1/NAP1/027) was isolated from 3 subjects (11%), 2 of whom displayed C. difficile associated diarrhea (CDAD) symptoms at the time of sampling. Emerging ribotypes with enhanced virulence (078 and 018) were also isolated from two asymptomatic subjects. Pyrosequencing of rRNA gene amplicons was used to determine the composition of the fecal microbiota as a surrogate for the microbial population structure of the distal intestine. Asymptomatic subjects (n = 20) from whom C. difficile was isolated showed no dramatic difference at the phylum or family taxonomic level compared to those that were culture negative (n = 252). However, in contrast, a marked reduction in microbial diversity at genus level was observed in patients who had been diagnosed with CDAD at the time of sampling and from whom C. difficile R027 was isolated.

Citing Articles

Gut Microbiota and New Microbiome-Targeted Drugs for Infections.

Lee A, Yoo J, Yoon E Antibiotics (Basel). 2024; 13(10).

PMID: 39452261 PMC: 11505460. DOI: 10.3390/antibiotics13100995.


The role and mechanism of gut-lung axis mediated bidirectional communication in the occurrence and development of chronic obstructive pulmonary disease.

Song X, Dou X, Chang J, Zeng X, Xu Q, Xu C Gut Microbes. 2024; 16(1):2414805.

PMID: 39446051 PMC: 11509012. DOI: 10.1080/19490976.2024.2414805.


Virulence factors, antibiotic susceptibility and sequence type distribution of hospital-associated Clostridioides difficile isolates in Israel, 2020-2022.

Schwartz O, Rohana H, Azrad M, Shor A, Rainy N, Maor Y Sci Rep. 2024; 14(1):20607.

PMID: 39232075 PMC: 11375014. DOI: 10.1038/s41598-024-71492-2.


Protective Effects of Huo Xiang Zheng Qi Liquid on Infection on C57BL/6 Mice.

Chen M, Zhai L, Schonning K, Alpizar-Alpizar W, Larum O, Andersen L Microorganisms. 2024; 12(8).

PMID: 39203444 PMC: 11356083. DOI: 10.3390/microorganisms12081602.


Efficacy of fidaxomicin versus vancomycin in the treatment of Clostridium difficile infection: A systematic meta-analysis.

Zhao Z, Wu Y, Geng X, Yuan C, Fu Y, Yang G Medicine (Baltimore). 2024; 103(32):e39213.

PMID: 39121324 PMC: 11315571. DOI: 10.1097/MD.0000000000039213.


References
1.
Friswell M, Campbell B, Rhodes J . The role of bacteria in the pathogenesis of inflammatory bowel disease. Gut Liver. 2010; 4(3):295-306. PMC: 2956340. DOI: 10.5009/gnl.2010.4.3.295. View

2.
Rea M, Sit C, Clayton E, OConnor P, Whittal R, Zheng J . Thuricin CD, a posttranslationally modified bacteriocin with a narrow spectrum of activity against Clostridium difficile. Proc Natl Acad Sci U S A. 2010; 107(20):9352-7. PMC: 2889069. DOI: 10.1073/pnas.0913554107. View

3.
Baines S, OConnor R, Freeman J, Fawley W, Harmanus C, Mastrantonio P . Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J Antimicrob Chemother. 2008; 62(5):1046-52. DOI: 10.1093/jac/dkn313. View

4.
Kuijper E, Barbut F, Brazier J, Kleinkauf N, Eckmanns T, Lambert M . Update of Clostridium difficile infection due to PCR ribotype 027 in Europe, 2008. Euro Surveill. 2008; 13(31). View

5.
Sokol H, Seksik P, Rigottier-Gois L, Lay C, Lepage P, Podglajen I . Specificities of the fecal microbiota in inflammatory bowel disease. Inflamm Bowel Dis. 2006; 12(2):106-11. DOI: 10.1097/01.MIB.0000200323.38139.c6. View